Johann Wolfgang Goethe University Hospital
kgu.deLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
159
Active
4
Phase 3
10
Total enrollment
1,183,347
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| NK-92/5.28.z | — | — | — | — | — | 1 | |
| Ezabenlimab | — | — | — | — | — | 1 |
Next readouts
- 2027-12-31
Top conditions
- Ataxia Telangiectasia6
- Heart Failure6
- Allergic Asthma5
- Bronchiolitis Obliterans4
- Coronary Artery Disease4
- Asthma3
- Allergy3
- Anemia3
Frequently asked questions about Johann Wolfgang Goethe University Hospital
- How many clinical trials does Johann Wolfgang Goethe University Hospital have on ClinicalTrials.gov?
- Johann Wolfgang Goethe University Hospital is listed as the lead sponsor on 159 clinical trials in ClinicalTrials.gov, 4 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Johann Wolfgang Goethe University Hospital's trials are in Phase 3?
- 10 of Johann Wolfgang Goethe University Hospital's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Johann Wolfgang Goethe University Hospital focus on?
- Johann Wolfgang Goethe University Hospital's most-studied conditions on ClinicalTrials.gov are Ataxia Telangiectasia, Heart Failure, Allergic Asthma, Bronchiolitis Obliterans, Coronary Artery Disease.
- When are Johann Wolfgang Goethe University Hospital's next clinical trial readouts?
- Johann Wolfgang Goethe University Hospital has 1 upcoming primary-completion readout tracked here; the soonest is “Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma”, expected around 2027-12-31.